Did the World Just Gain Hundreds of Millions of Alzheimer's Patients? A new definition of Alzheimer's includes people without symptoms. Experts are fiercely divided over whether that makes sense--and whether the new drugs really help. Many have heralded a golden age of Alzheimer's research, excited by the promise of new amyloid-targeting antibodies. Yet a large meta-study of such antibodies concluded that they probably result in "little to no difference" in the decline of memory and of cognitive ability. This July, some ten thousand people descended on London for the Alzheimer's Association International Conference. Another three thousand of us joined virtually. I'm an anthropologist, accustomed to conferences where croissants at coffee breaks count as a luxury. This one opened with six trumpeters dressed as Buckingham Palace guards, followed by dancers who discoed, vogued, and high-kicked through the history of British pop. After the first day's sessions, participants dispersed to parties; at one, singers in sequins belted out covers while someone played an illuminated, transparent violin. One night, the London Eye was lit purple to honor the people in attendance. The mood matched the spectacle. Joanne Pike, the Alzheimer's Association's president and C.E.O., announced that recent advances had brought the campaign against the disease to a "pivotal moment." Maria Carrillo, its chief science officer, hailed a groundswell of progress. That optimism followed decades of disappointment. Between 1974 and 2020, the U.S. government spent roughly twenty billion dollars on Alzheimer's research without seeing the approval of a single treatment designed to act on the disease's underlying biology, let alone stop or reverse its course. Today, Alzheimer's afflicts roughly one in nine Americans over sixty-five and, along with related dementias, has been estimated to cost the economy about three-quarters of a trillion dollars a year. In surveys, it ranks with cancer as the disease people fear most. It typically starts by robbing patients of recent memories--conversations they just had, where they put important objects--before corroding the basic functions of adult independence, from paying bills to managing medications. Eventually, it leaves patients unable to speak, move, swallow, or recognize close relatives.

Welcome to our monthly digest, where you can catch up with any AIhub stories you may have missed, peruse the latest news, recap recent events, and more. This month, we chat to AI pioneer, Michael Littman, learn about time-series forecasting for clinical data, investigate evolutionary game theory for cybersecurity, and get the scoop on neuromorphic computing. In the latest interview in our series meeting AI pioneers, Michael Littman reflects on the evolution of reinforcement learning, the power of science communication, and how generative AI is changing the way we teach and learn. Mayra Elwes is a PhD student developing machine learning methods for clinical time-series data. She is working on practical strategies to evaluate methods in a more contextualised way and on improving existing domain adaptation methods specific to time-series forecasting.

You're viewing the US edition You can switch to the UK, AU or IE homepage at any time using this menu. Shocking moment Trump is silenced at rally by heckler screaming'Shove that ballroom up your fat...' Mom of soccer prodigy, 3, kicked out of game for'being too good' raises thousands in fundraiser to make sure he keeps playing Jaw-dropping new photos reveal most detailed look yet at Taylor Swift's wedding: Inside the reception... and how they hid elaborate planning for months Elizabeth Holmes' prison secrets revealed by her jail bestie after bombshell documentary: Her private traumas and'diet' woes laid bare in detailed account of life behind bars Miracle new'Ozempic of autism' drug cured my son's worst symptoms... just days after taking his first pill: Breakthrough treatment poised to explode across globe as clinical trial leader says he'almost fainted' at the results New poll reveals the troubling numbers behind Democrats' commanding midterm lead... and why Republicans still ...

The vaccine is personalized to a patient's tumor, and results from the Phase 3 trial are yet another example of the promise of mRNA vaccines in treating cancer. The new mRNA vaccine is waiting on FDA approval but has shown great promise in Phase 3 clinical trials. An experimental vaccine offers new hope to patients with melanoma, one of the most aggressive forms of skin cancer . The pharmaceutical companies Merck and Moderna released the results of a Phase 3 clinical trial that evaluated the efficacy of a personalized mRNA-based vaccine that, when combined with immunotherapy, reduced the risk of disease recurrence or death by 42 percent compared to treatment with the immunotherapy drug alone. Georgina Long, medical director of the Australian Melanoma Institute and the study's principal investigator, said in a statement that these results are "transformative" and "have the potential to make a foundational shift in how we treat patients with earlier-stage melanoma."

Follow this section to personalize your feed and get instant alerts. Follow Go to your personalized feed WHY FOLLOW? Smart Alerts: Get notified about major news as it happens. Follow this tag to personalize your feed and get instant alerts. Follow Go to your personalized feed WHY FOLLOW?

The amount of time children in England spend on screens at school could be harming their physical and developmental health, a group of more than 150 clinicians has warned. GPs, paediatricians and other specialists said in an open letter to Education Secretary Lucy Powell and Health Secretary Yvette Cooper that tablets and laptops are being used without a full understanding of their long-term health impacts, including on eye health. The clinicians said they are prescribing glasses, hearing aids and speech therapy to children for a problem that is unintentionally being made worse in our schools. The government said it was consulting on screen time guidance for children aged five to 18 but that technology could be a powerful learning tool if used properly. The group of clinicians said nearly one million children are using screens in most lessons, despite studies suggesting a rise in short-sightedness.

Every minute without CPR and defibrillation reduces the chance of surviving a cardiac event by 10%. Every minute without CPR and defibrillation reduces the chance of surviving a cardiac event by 10%. Drones could help cut the time it takes to get a defibrillator to people experiencing cardiac arrests when not in hospital, researchers have suggested. In the UK alone, there are more than 30,000 out-of-hospital cardiac arrests a year where emergency medical services attempt to resuscitate the individual, according to the British Heart Foundation. However, fewer than one in 10 people survive such an event, and some who do are left with neurological problems. One important factor that can affect survival is how rapidly victims get access to treatment - every minute without CPR and defibrillation reduces the chance of survival by 10% .

Follow this author to personalize your feed and get instant alerts. Follow Go to your personalized feed WHY FOLLOW? Smart Alerts: Get notified about major news as it happens. Follow this author to personalize your feed and get instant alerts. Follow Go to your personalized feed WHY FOLLOW?

I wore the world's first HDR10 smart glasses TCL's new E Ink tablet beats the Remarkable and Kindle Anker's new charger is one of the most unique I've ever seen I wore the world's first HDR10 smart glasses TCL's new E Ink tablet beats the Remarkable and Kindle Anker's new charger is one of the most unique I've ever seen Research suggests a gap between AI ambition and on-the-ground reality, but the good news is that professionals can fill it by focusing on well-grounded explorations and solid production use cases. Professionals believe AI isn't delivering value. Too many organizations suffer from tool blast. Focus on strong use cases to deliver uplift. As many as 91% of employees say their organization is falling short of reaching the value that AI can deliver, according to the 2026 Future of Professionals Report from global content and technology company Thomson Reuters.

The study examined 97,364 breast scans from 29,921 women who had an average age of 54. The study examined 97,364 breast scans from 29,921 women who had an average age of 54. Doctors have discovered a way to use routine mammograms that screen for breast cancer to spot heart disease, the world's leading - and frequently underdiagnosed - cause of death in women. Researchers analysed the scans using artificial intelligence and were able to successfully identify women with coronary heart disease, high blood pressure or who had suffered a stroke. Experts said it meant breast screening for cancer could become dual-purpose, helping to flag women with heart disease, and other cardiovascular issues, as well as spotting breast cancer early.